FY2026 · ended May 31, 2026 · Revenue $4.45M, -16.2% YoY · Filed Aug 31, 2026
Biomerica, Inc. (BMRA) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In fiscal 2026, which ended May 31, 2026, it reported revenue of $4.5 million and a net loss of $3.8 million. As of Aug 31, 2026 it held $2.7 million in cash and investments and $1.8 million in total debt.
Revenue (TTM)
$4.34M
-11.2% vs year-ago TTM
Net income (TTM)
$-5.01M
-37.0% vs year-ago TTM
Operating cash flow (TTM)
$-3.96M
-43.0% vs year-ago TTM
Free cash flow
$-5.41M
+2.3% vs prior year
EPS (TTM)
$-1.63
-8.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
4.60M
+0.2% vs prior year
Net cash
$907,000
as of Aug 31, 2026
Operating margin
-125.1%
FY 2027
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- BMRA (Nasdaq)
- Fiscal year ends
- May 31
- Incorporated in
- DE
- Headquarters
- Irvine, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 73290
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 May 31, 2026 |
FY 2025 May 31, 2025 |
FY 2024 May 31, 2024 |
FY 2023 May 31, 2023 |
FY 2022 May 31, 2022 |
|---|---|---|---|---|---|
| Revenue | $4.5M | $5.3M | $5.4M | $5.3M | $18.9M |
| Operating income | -$5.3M | -$5.1M | -$6.4M | -$7.2M | -$4.5M |
| Net income | -$3.8M | -$5.0M | -$6.0M | -$7.1M | -$4.5M |
| Diluted EPS | -$1.30 | -$2.16 | -$2.84 | -$0.50 | -$0.36 |
| Operating cash flow | -$3.4M | -$3.8M | -$5.4M | -$5.5M | -$479,000 |
| Free cash flow | — | — | -$5.4M | -$5.5M | -$536,000 |
| Total assets | $6.8M | $5.9M | $9.3M | $14.5M | $11.4M |
| Total liabilities | $4.1M | $1.8M | $2.7M | $2.7M | $3.0M |
| Stockholders' equity | $2.6M | $4.1M | $6.6M | $11.7M | $8.3M |
| Cash and investments | $1.3M | $2.4M | $4.2M | $9.7M | $5.9M |
| Total debt | $1.9M | $458,000 | $785,000 | $1.1M | $1.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 15, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 15, 2026 | Oct 9, 2026 |
| 10-K/A | Amended annual report | Sep 28, 2026 | May 31, 2026 |
| 10-K | Annual report | Aug 31, 2026 | May 31, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Aug 26, 2026 | Aug 20, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Jun 4, 2026 | May 29, 2026 |
All 605 Biomerica, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.